{
    "RADCURE-0765": {
        "question": "Age: 49.8, Sex: Female, ECOG PS: ECOG 1, Smoking PY: 35, Smoking Status: Current, Ds Site: Esophagus, Subsite: Cervical esophagus, T: T2, N: N0, M : M0, Stage: none, Path: carcinoma, HPV: none, Tx Modality: ChemoRT, Chemo? : Yes, Dose: 70.0, Fx: 35, Local: none, Regional: none, Distant: none, 2nd Ca: none, ContrastEnhanced: 1\nAnswer: ",
        "recruit-recruiter": "1. Radiation Oncologist - Your expertise is strictly limited to radiation therapy planning and dosing for esophageal carcinoma, especially in cervical esophagus cases treated with chemoradiotherapy. - Hierarchy: Radiation Oncologist",
        "initial_assessment-radiation oncologist": "**Step 1: Initial Assessment of the CT Scan (without bounding box data)**\n\n- The image is a sagittal CT scan of the head and neck region.\n- The vertebral column is clearly visible, showing normal alignment without obvious fractures or deformities.\n- The airway (pharynx and cervical trachea) is patent and appears to be of normal caliber.\n- Soft tissue structures anterior to the vertebrae include the esophagus and surrounding musculature.\n- There is a masked region of interest (ROI) located anterior to the cervical vertebrae, likely corresponding to the cervical esophagus region.\n- No grossly visible masses or abnormal calcifications are noted in this single slice.\n- No obvious lymphadenopathy or abnormal soft tissue swelling is seen in this view.\n- The spinal cord is visible within the vertebral canal without apparent compression.\n\n**Step 2: Mapping Bounding Boxes**\n\nBounding box coordinates are given as:\n\n- Box 1: [253, 202, 119, 253, 238, 141]\n- Box 2: [255, 226, 93, 255, 304, 179]\n\nThese coordinates correspond to normalized indices along z, y, and x axes.\n\n- Box 1 is a smaller volume located roughly in the mid-cervical region, likely encompassing part of the cervical esophagus and adjacent soft tissues.\n- Box 2 is a larger volume extending more inferiorly and anteriorly, possibly including a larger segment of the cervical esophagus and regional lymphatic structures.\n\nThese bounding boxes likely delineate the primary tumor volume and possibly involved regional lymph nodes or areas at risk for microscopic disease.\n\n**Step 3: Clinical Reasoning**\n\n- Patient has cervical esophageal carcinoma, treated with chemoradiotherapy (70 Gy in 35 fractions).\n- The masked ROI and bounding boxes correspond to the tumor and regional areas targeted for radiation.\n- The absence of visible gross nodal disease on this slice suggests N0 status, consistent with the clinical data.\n- The tumor is localized (T2), no distant metastases (M0).\n- ECOG 1 indicates the patient is ambulatory and capable of self-care, which is favorable for treatment tolerance.\n- Smoking history is significant (35 pack-years, current smoker), which may impact prognosis negatively.\n- The radiation dose and fractionation are standard for definitive chemoradiotherapy in cervical esophageal carcinoma.\n- No evidence of local or regional progression on this scan.\n- The spinal cord and airway are spared from high-dose radiation, reducing risk of severe toxicity.\n\n**Step 4: Integrated Conclusion**\n\n- The CT scan and bounding boxes confirm a localized cervical esophageal carcinoma without evident nodal or distant spread.\n- The patient is receiving definitive chemoradiotherapy with an adequate dose.\n- Clinical performance status and tumor stage suggest a reasonable chance of local control.\n- Smoking status is a negative prognostic factor but does not preclude favorable outcome.\n- Overall, the imaging and clinical data support a good likelihood of survival with current treatment.\n\n('Answer:Alive',)",
        "Round 1-role-comment": "radiation oncologist:alive",
        "Round 1-num_agents": 1,
        "Round 2-Turn 1-discuss-participate-radiation oncologist": "No",
        "Round 2-Turn 1-ask_gap-radiation oncologist": "Yes. A medical oncologist or a head and neck surgical oncologist would be beneficial to provide input on systemic therapy options, surgical considerations, and overall multidisciplinary management beyond radiation therapy planning and dosing. This is important for comprehensive care of cervical esophageal carcinoma, especially given the patient's smoking history and potential need for supportive care or treatment modifications.",
        "Round 2-Turn 1-gap_identified-assistant": "A unique, useful, and specific expert recommendation extracted from the discussion is:\n\n- Consult a medical oncologist or a head and neck surgical oncologist to provide input on systemic therapy options, surgical considerations, and overall multidisciplinary management beyond radiation therapy planning and dosing for comprehensive care of cervical esophageal carcinoma.",
        "Round 2-Turn 1-gap_recruit-recruiter": "1. Medical Oncologist - Your expertise is strictly limited to systemic therapy decisions, including chemotherapy and immunotherapy in esophageal carcinoma, with a focus on integrating systemic treatment with radiation therapy. - Hierarchy: Medical Oncologist == Radiation Oncologist",
        "Round 2-Turn 1-gap_recruited_assessment-medical oncologist": "**Step 1: Initial Assessment of the CT Scan (without bounding box data)**\n\n- The image is a sagittal contrast-enhanced CT scan of the head and neck region.\n- The cervical vertebrae are well-aligned without fractures or deformities.\n- The spinal canal and spinal cord are visible and appear intact without compression.\n- The airway (pharynx and cervical trachea) is patent and of normal caliber.\n- Soft tissues anterior to the vertebral bodies include the esophagus and surrounding musculature.\n- There is a masked region of interest (ROI) located anterior to the cervical vertebrae, likely corresponding to the cervical esophagus.\n- No grossly visible masses or abnormal calcifications are noted in this slice.\n- No obvious lymphadenopathy or abnormal soft tissue swelling is seen.\n- No signs of local invasion into adjacent structures are apparent.\n- The contrast enhancement helps delineate vascular and soft tissue structures clearly.\n\n**Step 2: Mapping Bounding Boxes**\n\nBounding box coordinates:\n\n- Box 1: [253, 202, 119, 253, 238, 141]\n- Box 2: [255, 226, 93, 255, 304, 179]\n\nThese normalized coordinates correspond to specific volumetric regions within the scan:\n\n- Box 1 is a smaller volume located in the mid-cervical region, likely encompassing the primary tumor in the cervical esophagus and adjacent soft tissues.\n- Box 2 is a larger volume extending inferiorly and anteriorly, possibly including a larger segment of the cervical esophagus and regional lymphatic drainage areas.\n- These boxes likely represent the gross tumor volume (GTV) and clinical target volume (CTV) for radiation planning.\n\n**Step 3: Clinical Reasoning**\n\n- Patient is a 49.8-year-old female with cervical esophageal carcinoma, staged T2N0M0.\n- ECOG performance status 1 indicates good functional status.\n- Smoking history is significant (35 pack-years, current smoker), which may negatively impact prognosis and treatment tolerance.\n- The patient is undergoing definitive chemoradiotherapy with a total dose of 70 Gy in 35 fractions, which is standard for curative intent.\n- The masked ROI and bounding boxes correspond to the tumor and regional areas targeted for radiation.\n- No evidence of nodal or distant metastases on imaging.\n- The airway and spinal cord are spared from high-dose radiation, minimizing risk of severe toxicity.\n- The absence of gross nodal disease and localized tumor stage suggest a favorable prognosis.\n- Smoking status is a risk factor for treatment complications and secondary malignancies but does not preclude good outcome.\n- Overall, the patient is likely to tolerate treatment well and achieve local control.\n\n**Step 4: Integrated Conclusion**\n\n- Imaging confirms a localized cervical esophageal carcinoma without nodal or distant spread.\n- The masked ROI and bounding boxes correspond to the tumor and at-risk regional tissues targeted by chemoradiotherapy.\n- The patientâ€™s good performance status and standard treatment regimen support a favorable prognosis.\n- Smoking history is a negative prognostic factor but manageable.\n- The imaging and clinical data collectively indicate a good likelihood of survival with current treatment.\n\n('Answer:Alive',)",
        "Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-medical oncologist": "No",
        "Round 2-role-comment": "radiation oncologist:alive|medical oncologist:alive",
        "Round 2-num_agents": 2,
        "num_cooperations-panel": 0,
        "decision-Moderator": "('Answer: Alive',)"
    }
}